Home/ Stocks/ INAB

IN8bio, Inc. Common Stock

INAB XNAS

$0.98 +0.01 (+0.90%) ▲ 15-min delayed

Open

$0.97

High

$0.98

Low

$0.95

Volume

36.6K

Market Cap

$9.55M

About IN8bio, Inc. Common Stock

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 18 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$176.0K	$-5,090,000	$-0.26
FY 2025	$421.0K	$-19,440,000	$-4.44
Q3 2025	$113.0K	$-3,854,000	$-0.85
Q2 2025	$107.0K	$-5,094,000	$-1.24

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for INAB yet. Check out our latest market news or earnings calendar.

Get INAB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on IN8bio, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.